Ranbaxy
EU lifts ban on Ranbaxy’s Toansa-made drugs
06 Jun 2014
European regulators on Thursday lifted the EU ban on drugs manufactured at Ranbaxy Laboratories' Toansa plant, saying they do not pose a risk to public health
AP High Court vacates stay on Ranbaxy-Sun Pharma merger
24 May 2014
The Andhra Pradesh High Court has vacated a stay on the proposed merger of Ranbaxy Laboratories with Sun Pharma over alleged insider trading in Ranbaxy shares ahead of the merger announcement
SC blasts manner of stalling Sun-Ranbaxy merger
21 May 2014
Sun Pharma denied the charge but said the share purchase by Silver Street, a limited-liability partnership firm owned by two subsidiaries of Sun Pharma, was being annulled
HC blocks Ranbaxy-Sun Pharma merger over insider trading allegations
30 Apr 2014
The order was in response to a petition for a Sebi inquiry into possible insider trading in Ranbaxy shares that saw heavy trading before the merger with Sun Pharma was announced
Ranbaxy drug flows to Europe, US to dry up
09 Apr 2014
Sun Pharmaceutical Industries plans to phase out sales of Ranbaxy’s branded generic drugs in the US while continuing sales in other markets
Sun Pharma, Ranbaxy to merge in Rs24,000 all-stock deal
07 Apr 2014
The merger will create India's largest pharmaceutical company and the world's fifth largest speciality generics company with annual emerging market sales nearing Rs6,000 crore
Shocking dosage mix-up forces Ranbaxy to recall generic Liptor in US
08 Mar 2014
Quality concerns about India's $14 billion drug industry have come to the fore after the US FDA banned plants run by Ranbaxy and Wockhardt Ltd from sending drugs to the US, for failure to meet manufacturing standards
SC throws out PIL against Ranbaxy over substandard drug issue
25 Jun 2013
Ranbaxy, the largest drug maker in India, is under attack, both because of its size and reach and the threat its generic drugs pose to the patent drugs lobby, especially in the West
European regulator fines Ranbaxy and 8 others for blocking generic drugs
19 Jun 2013
The European antitrust regulator today fined nine pharmaceutical companies including Ranbaxy a total of €146 million for blocking the supply of a cheaper anti-depressant drug to the market.
Indian doctors’ body asks DCGI to probe Ranbaxy drug quality
29 May 2013
The Indian Medical Association has asked the Drug Controller General of India to investigate the quality of drugs manufactured and sold by Ranbaxy Laboratories in India
Ranbaxy fined $500 mn by US regulator over drug safety lapses
14 May 2013
Ranbaxy Laboratories Ltd yesterday agreed to pay a record $500 million fine to settle a US civil and criminal lawsuit brought on by a whistle-blower and the US regulator
Featured articles
Lighter than air, yet very, very powerful
By Kiron Kasbekar | 03 Jan 2024
In March 2013 Chinese scientists pulled off a remarkable feat. They created the world’s lightest aerogel. Tipping the scales at a mere 0.16 milligrams per cubic centimeter – that’s a sixth of the weight of air!
COP28 explained: A closer look at COP28's climate change solutions
By Aniket Gupta | 27 Dec 2023
The 28th United Nations Climate Change Conference, also known as COP28, took place from 30th November 2023, to 13th December 2023, at Expo City in Dubai, United Arab Emirates.
What is a Ponzi scheme?
By Aniket Gupta | 06 Dec 2023
Ponzi schemes have long captivated the public imagination, drawing unsuspecting investors into a web of illusion and deception.
The Rise and Rise of HDFC Bank
03 Jul 2023
HDFC, which surged ahead of global majors like HSBC Holdings Plc and Citigroup Inc and left Indian peers like State Bank of India and ICICI Bank in market capitalisation, now ranks fourth largest among the world’s most valuable banks, after JPMorgan Chase & Co, Industrial and Commercial Bank of China Ltd and Bank of America Corp
India’s Millet Revolution To Enrich Global Food Basket
02 Apr 2023
Millets, a healthier and cheaper substitute to wheat and rice, are indigenous to many parts of the world, especially in the semiarid tropics of Asia and Africa, and offers a big scope for expanding production and consumption in the foodgrain deficient African continent
Market predator Hindenburg preys on Adani stock
06 Mar 2023
Almost a month after the damning report of short-seller Hindenburg Research on the Adani Group that claimed that the seven stocks within the group were about 85 per cent overvalued, one of the group's stocks, Adani Total Gas, closed at Rs835 on the BSE, down nearly 79 per cent from its 24 January level, almost close to reaching that valuation
.jpg "Microsoft, Google challenge Delhi HC order to remove non-consensual content")
